

## BOARD OF DIRECTORS

**Judith Flores, MD, FAAP, CHQM**

*Chairwoman*  
Clinical Associate Professor  
New York University School of Medicine  
New York, NY

**Elena Rios, MD, MSPH**

*President & CEO*  
National Hispanic Medical Association,  
Washington, DC

**Nerieda Correa, MD**

*Chairwoman Elect*  
Associate Clinical Professor of Obstetrics,  
Gynecology and Women's Health  
Albert Einstein College of Medicine  
CEO, Eastchester Medical Associates, PC  
Bronx, NY

**Minerva Campos, MD, MPH**

*Secretary*  
Washington, DC

**Nelson Reyneri**

*Treasurer*  
Vice President, Sales and External Affairs,  
Liberty Power, Fort Lauderdale, FL

**Samuel Arce, MD, FAAFP**

*Immediate Past-Chairman*  
Family Physician and Attending Physician,  
Jamaica Hospital Medical Center,  
Jamaica, NY

**David Carlisle, MD, PhD**

*President and CEO,*  
Charles R. Drew University of Medicine  
& Biomedical Sciences, Los Angeles, CA

**Carlos Corral, MD, FACS**

*New Mexico Cardiovascular Associates*  
Las Cruces, NM

**Jorge A. Girotti, PhD, MA**

*Associate Dean and Director,*  
Special Curricular Programs, Admissions,  
Hispanic Center of Excellence  
Assistant Professor, Medical Education  
UIC College of Medicine, Chicago IL

**Ana Maria Lopez, MD, MPH, FACP**

*Associate Vice President for Health Equity  
and Inclusion, University of Utah Health  
Sciences Center, Director of Cancer Health  
Equity, Huntsman Cancer Institute,  
Professor of Medicine, University of Utah  
School of Medicine, Salt Lake City, Utah*

**Flavia E. Mercado, MD**

*Medical Director, Inovalon, Inc., Snelville, GA*

**Jorge G. Puenté, MD**

*Managing Partner*  
Pleasanton Pharma Ventures, Northport, NY

**Diana Ramos, MD, MPH**

*Director, Reproductive Health,*  
Los Angeles County Public Health, CA

**Vanessa Salcedo, MD, MPH, FAAP**

*Chairwoman, NHMA Council of Young Physicians*  
Union Community Health Center, New York, NY

**Eric Molina**

*President, Latino Medical Student Association*  
Baylor College of Medicine, Houston, TX

**Sonia Morales, MD MPH**

*Pediatrics Co Chief Resident, Harbor-UCLA*  
Pediatrics Department, Torrance, CA

**Claudia H. Zamora, MPA**

*Healthcare Strategy, Operations and*  
Implementation Consultant, Washington, DC

## ADVISORY COUNCIL

**Richard H. Carmona, MD, MPH, FACS**

*17<sup>th</sup> US Surgeon General (2002-2006)*  
Vice Chairman, Canyon Ranch Institute  
Distinguished Professor,  
Zuckerman College of Public Health,  
University of Arizona, Tucson, AZ

**Henry Cisneros**

*Chairman, CityView, San Antonio, TX*

**Ronald Estrada**

*Vice President, National Community*  
Empowerment, Univision, Washington, DC

**Linda Griego**

*President & CEO, Griego Enterprises, Inc.*  
Los Angeles, CA

**Paloma Hernandez, MPH, MS**

*President & CEO Urban Health Plan, Inc., Bronx, NY*

**Yasmine Winkler, MBA**

*Senior VP Innovation and Productivity*  
United HealthCare, Chicago, IL

**Richard Zapanta, MD**

*Orthopedic Surgeon, Monterey Park, CA*



January 17, 2018

Senate Health and Human Services Committee  
South Dakota State Capitol  
500 E Capitol Ave.  
Pierre, SD 57501

Dear Chair Soholt:

On behalf of the Board of Directors of the National Hispanic Medical Association, we urge you to vote yes for SB 75, FDA-designated interchangeable biological drug products.

This bill authorizes a pharmacist to substitute an alternative biological product when filling a prescription for a prescribed biological product if the alternative biological products is designated as interchangeable with the reference product and communication is provided to the patient and physician that a substitution was made. The bill would also require that the substitution of a biological product be communicated to the patient.

We recognize the rising use of biologics and biosimilars in our population now aging with increased chronic disease. Biosimilars go through an extensive review process and manufacturers are required to submit immense studies and data demonstrating a products' efficacy and ensuring it is safe for use by consumers. A pathway for biosimilar regulation in the U.S. was established as a provision of the 2008 Patient Protection and Affordable Care Act (ACA) and in 2012 the FDA issued draft guidelines for biosimilars and a list of biosimilars and interchangeable biological products.

In summary, the National Hispanic Medical Association recommends your support for SB 75 to clarify the procedures for biosimilar substitution for biologic treatments in a way that increases safety for the patient. We are especially supportive since this bill will provide increased access to quality treatment for Hispanics and all persons from South Dakota with chronic diseases.

Sincerely,

A handwritten signature in black ink that reads 'Elena Rios'.

Elena Rios, MD, MSPH, FACP  
President & CEO

CC: Members of the South Dakota State Senate